ProPhase Labs, Inc. (PRPH)

NASDAQ: PRPH · IEX Real-Time Price · USD
6.27
-1.08 (-14.69%)
At close: Apr 17, 2024, 4:00 PM
6.60
+0.33 (5.26%)
Pre-market: Apr 18, 2024, 4:38 AM EDT
-14.69%
Market Cap 113.14M
Revenue (ttm) 44.38M
Net Income (ttm) -16.78M
Shares Out 18.05M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE 10.09
Dividend n/a
Ex-Dividend Date n/a
Volume 82,436
Open 7.47
Previous Close 7.35
Day's Range 6.05 - 7.64
52-Week Range 4.05 - 9.94
Beta -0.27
Analysts Strong Buy
Price Target 11.00 (+75.44%)
Earnings Date May 9, 2024

About PRPH

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It also offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, in... [Read more]

Sector Healthcare
IPO Date Jan 16, 1997
Employees 113
Stock Exchange NASDAQ
Ticker Symbol PRPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PRPH stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(75.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ProPhase Labs Unveils Project ZenQ-AI

Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development.

1 day ago - GlobeNewsWire

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024

Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its p...

7 days ago - GlobeNewsWire

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced th...

16 days ago - GlobeNewsWire

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenu...

4 weeks ago - GlobeNewsWire

PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024

GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted...

5 weeks ago - GlobeNewsWire

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, g...

2 months ago - GlobeNewsWire

Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts

Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and Profitability Company in Late-Stage Discussions with Two Additional Large Global Brands ...

3 months ago - GlobeNewsWire

ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursda...

5 months ago - GlobeNewsWire

ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.

Pharmaloz plan is to build capacity with a goal to attain a revenue run-rate of $60 to $80 million by year-end 2024, with 20-25% pre-tax net margins and a goal for additional growth thereafter.

6 months ago - GlobeNewsWire

ProPhase Labs to Present at The ThinkEquity Conference

GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be participati...

6 months ago - GlobeNewsWire

ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call.

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) Conference Call and Webcast Details Management will host a conference call at 11:00 AM ET, Thursday, August 10, 20...

8 months ago - GlobeNewsWire

ProPhase Labs to Host Second Quarter 2023 Financial Results Conference Call on Thursday, August 10, 2023 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursda...

9 months ago - GlobeNewsWire

Navidea Biopharmaceuticals rejects ProPhase Labs offer

Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navi...

Other symbols: NAVB
10 months ago - Market Watch

ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies

In a bid to seize substantial strategic growth opportunities in an emerging healthcare market, Company reveals plans to increase its global footprint.

10 months ago - GlobeNewsWire

ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023

Garden City, NY, June 07, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that management will pr...

11 months ago - GlobeNewsWire

ProPhase Labs' Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing

Linebacker fully inhibited lung cancer cell growth and significantly limited colon cancer cell growth in two separate clonogenic models

11 months ago - GlobeNewsWire

ProPhase Labs hires Dr. Matthew Halpert to Drive Company's Key Therapeutic and Diagnostic Oncology Programs

GARDEN CITY, NY, May 08, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced that Dr. Matthew Halpert has been hir...

1 year ago - GlobeNewsWire

ProPhase Labs' Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its p...

1 year ago - GlobeNewsWire

ProPhase Labs CEO Ted Karkus Named One of Inc Magazine's 10 Most Innovative Healthcare Leaders to Watch in 2023

Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus...

1 year ago - GlobeNewsWire

ProPhase Labs Announces Launch of Redesigned Corporate Website

Garden City, NY, April 25, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today announced the launch of its newl...

1 year ago - GlobeNewsWire

ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022

Company highlights key strategic initiatives to grow underlying value in 2023 and beyond

1 year ago - GlobeNewsWire

ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test

Presentation to be given in Collaboration with the Mayo Clinic   at the   United States and Canadian Academy of Pathology   (USCAP) Annual Meeting

1 year ago - GlobeNewsWire

ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test

GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. “ProPhase” (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it h...

1 year ago - GlobeNewsWire

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be pres...

1 year ago - GlobeNewsWire

ProPhase Labs to Present at Investor Summit Group's Q4 Conference

GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participa...

1 year ago - GlobeNewsWire